Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia
September 27, 2020 20:05 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and...